Yes I think 2023 will be a very interesting year once we have some GBM Agile data considering we need only perform similarly as did in our previous GBM study - we needed a greater volume of study participants this time we have 150 in our arm + 300 in the control group on top of the previous study participants…
if results are similar I fully expect an announcement we are filling an FDA application.
our results were way better than Telozolomide which only worked in 30% of users - Pax worked in approx 66% and extended life longer than Telozolomide. Given some drugs are approved simply because they offer another choice without any proven life tension at all, I bet an application would be approved.
With one approval in GBM (or any condition) the value of all the other studies already working their way through stages for years will come sharply into focus within investor communities.
